These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8252687)

  • 21. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study.
    Zhao XQ; Yuan C; Hatsukami TS; Frechette EH; Kang XJ; Maravilla KR; Brown BG
    Arterioscler Thromb Vasc Biol; 2001 Oct; 21(10):1623-9. PubMed ID: 11597936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
    Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L
    JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-lowering therapy after coronary artery bypass grafting: time for more aggressive intervention.
    Lucas BD
    Am J Health Syst Pharm; 2002 Nov; 59(21):2101-3. PubMed ID: 12434726
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
    Barbir M; Hunt BJ; Galloway D; Taylor A; Ilsley C; Mitchell A; Yacoub M
    Clin Cardiol; 1994 Feb; 17(2):59-64. PubMed ID: 8162627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
    Furberg CD; Adams HP; Applegate WB; Byington RP; Espeland MA; Hartwell T; Hunninghake DB; Lefkowitz DS; Probstfield J; Riley WA
    Circulation; 1994 Oct; 90(4):1679-87. PubMed ID: 7734010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
    Blankenhorn DH; Selzer RH; Crawford DW; Barth JD; Liu CR; Liu CH; Mack WJ; Alaupovic P
    Circulation; 1993 Jul; 88(1):20-8. PubMed ID: 8319334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications.
    Paterson RW; Paat JJ; Steele GH; Hathaway SC; Wong JG
    South Med J; 1994 Feb; 87(2):236-42. PubMed ID: 8115891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.
    Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP
    Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial.
    Faulkner MA; Wadibia EC; Lucas BD; Hilleman DE
    Pharmacotherapy; 2000 Apr; 20(4):410-6. PubMed ID: 10772372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
    Thompson GR; Maher VM; Matthews S; Kitano Y; Neuwirth C; Shortt MB; Davies G; Rees A; Mir A; Prescott RJ
    Lancet; 1995 Apr; 345(8953):811-6. PubMed ID: 7898227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.
    Malloy MJ; Kane JP; Kunitake ST; Tun P
    Ann Intern Med; 1987 Nov; 107(5):616-23. PubMed ID: 3662275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study.
    Brown BG; Hillger L; Zhao XQ; Poulin D; Albers JJ
    Ann N Y Acad Sci; 1995 Jan; 748():407-17; discussion 417-8. PubMed ID: 7695184
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
    Schrott HG; Stein EA; Dujovne CA; Davidson MH; Goris GB; Oliphant TH; Phillips JC; Shawaryn GG
    Am J Cardiol; 1995 Jan; 75(1):34-9. PubMed ID: 7801861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).
    Haskell WL; Alderman EL; Fair JM; Maron DJ; Mackey SF; Superko HR; Williams PT; Johnstone IM; Champagne MA; Krauss RM
    Circulation; 1994 Mar; 89(3):975-90. PubMed ID: 8124838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
    Voros S; Joshi PH; Vazquez G; Roth G; Murrieta L; Rinehart S; Qian Z; Miller J
    J Cardiovasc Comput Tomogr; 2010; 4(3):164-72. PubMed ID: 20413364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.